Prevention of Asthma Relapse After Discharge from Emergency - PARADE

Study identifier:D5890L00017

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A comparison of budesonide/formoterol Turbuhaler® 160/4.5 µg 2 inhalations BID plus as needed to budesonide Turbuhaler® 320 µg 2 inhalations BID plus terbutaline Turbuhaler® 0.4 mg as needed for the prevention of asthma relapse

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Budesonide/formoterol

Sex

All

Actual Enrollment

600

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 May 2006
Primary Completion Date: -
Study Completion Date: 01 May 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria